BCR and leukemia: We first analyzed the pharmacologic interactions between the MEKi Mirdametinib (PD0325901; indicated as PD) and ATO using a fixed-ratio experimental design on Ph+ leukemia cell lines displaying different degrees of resistance to the first, second, and third generation of BCR::ABL1 TKIs [20, 21].